KEYWORDSmultidrug resistance (MDR), panresistance, antimicrobial peptide (AMP), AMPencoding mRNA, in vitro transcribed, in vivo translated AMP-encoding mRNA, antimicrobial nucleic acid therapy Editorial on the Research Topic Antimicrobial peptides and mRNA therapy: Clinical, Veterinary and plant pathology perspectives with special attention to combatting MDR pathogens Antimicrobial multidrug resistance (MDR) of the different types is an enormous challenge of clinical, veterinary, and plant pathogenic significance (Fodor et al., 2020). Antimicrobial peptides (AMPs) (Ötvös and Wade, 2014;Upert et al., 2021) are of great potential against MDR pathogens, because (a) the MDR pathogens perform a high frequency of collateral sensitivity to AMPs (Fodor et al., 2022); (b) the mobility patterns of antibiotic resistance and AMP-resistance genes are different (Lázár et al., 2018). The delivery of an exogenous AMP to the right location of a eukaryotic organism is a crucial point. This explains the setting of the ambitious goal to invite authors of manuscripts on delivering in vitro transcribed (exogenous) AMP-into the cell to be protected, in order to translate it to the respective protective AM-peptide in site, following the logic of mRNAbased vaccination (Sahin et al., 2020;Karikó et al., 2021). Unfortunately no manuscript like that was submitted. Instead, we received valuable papers within the larger scope of the RT dealing with perspectives of AMPs solving MDR-related problems.The Research Topics (RT), comprise two Reviews and two Original Research papers from the field of antimicrobial resistance. A Review (Le et al.) discusses the sources and mechanisms of antimicrobial peptides (AMPs) against staphylococcal species including Staphylococcus aureus, S. haemolyticus, Frontiers in Microbiology frontiersin.org